3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:千円) |
| 前連結会計年度 (2025年3月31日) | 当連結会計年度 (2026年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 23,592,676 | 27,760,027 |
受取手形 | 243,962 | - |
電子記録債権 | - | 35,486 |
売掛金 | 26,498,203 | 31,413,406 |
商品及び製品 | 8,592,660 | 10,994,264 |
仕掛品 | 2,352,119 | 3,551,515 |
原材料及び貯蔵品 | 5,489,107 | 6,351,030 |
その他 | 2,892,079 | 3,200,118 |
貸倒引当金 | △131,114 | △658,965 |
流動資産合計 | 69,529,694 | 82,646,882 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物 | 26,531,377 | 27,941,819 |
減価償却累計額 | △19,913,607 | △20,835,015 |
建物及び構築物(純額) | 6,617,770 | 7,106,803 |
機械装置及び運搬具 | 16,800,871 | 18,657,215 |
減価償却累計額 | △15,147,512 | △15,726,455 |
機械装置及び運搬具(純額) | 1,653,359 | 2,930,759 |
土地 | 12,658,498 | 12,663,993 |
建設仮勘定 | 3,617,496 | 2,905,397 |
その他 | 7,458,612 | 8,062,076 |
減価償却累計額 | △5,364,292 | △6,069,647 |
その他(純額) | 2,094,319 | 1,992,428 |
有形固定資産合計 | 26,641,444 | 27,599,383 |
無形固定資産 | | |
のれん | 3,621,171 | 3,027,507 |
販売権 | 27,950,775 | 27,088,898 |
商標権 | 7,641,312 | 7,821,831 |
その他 | 1,148,423 | 1,643,550 |
無形固定資産合計 | 40,361,683 | 39,581,788 |
投資その他の資産 | | |
投資有価証券 | 8,865,571 | 10,112,376 |
繰延税金資産 | 97,940 | 84,760 |
退職給付に係る資産 | 13,264,717 | 19,294,530 |
その他 | 443,262 | 407,314 |
貸倒引当金 | △32,717 | △29,086 |
投資その他の資産合計 | 22,638,773 | 29,869,895 |
固定資産合計 | 89,641,902 | 97,051,067 |
資産合計 | 159,171,596 | 179,697,949 |
| | (単位:千円) |
| 前連結会計年度 (2025年3月31日) | 当連結会計年度 (2026年3月31日) |
負債の部 | | |
流動負債 | | |
買掛金 | 3,971,467 | 4,895,991 |
短期借入金 | 34,298,379 | 33,834,190 |
未払法人税等 | 3,773,088 | 4,827,849 |
賞与引当金 | 1,623,664 | 1,778,324 |
その他 | 10,782,461 | 10,371,773 |
流動負債合計 | 54,449,062 | 55,708,129 |
固定負債 | | |
長期借入金 | 6,865,780 | 5,269,740 |
繰延税金負債 | 6,496,077 | 8,586,947 |
退職給付に係る負債 | 224,138 | 201,368 |
資産除去債務 | 56,451 | 56,629 |
その他 | 1,283,058 | 1,270,343 |
固定負債合計 | 14,925,506 | 15,385,029 |
負債合計 | 69,374,568 | 71,093,159 |
純資産の部 | | |
株主資本 | | |
資本金 | 6,593,398 | 6,593,398 |
資本剰余金 | 11,685,121 | 5,620,541 |
利益剰余金 | 67,207,063 | 73,545,791 |
自己株式 | △18,266,472 | △12,204,622 |
株主資本合計 | 67,219,110 | 73,555,108 |
その他の包括利益累計額 | | |
その他有価証券評価差額金 | 2,108,422 | 3,069,779 |
為替換算調整勘定 | 16,995,687 | 24,628,069 |
退職給付に係る調整累計額 | 3,216,617 | 7,143,784 |
その他の包括利益累計額合計 | 22,320,727 | 34,841,632 |
非支配株主持分 | 257,189 | 208,048 |
純資産合計 | 89,797,027 | 108,604,790 |
負債純資産合計 | 159,171,596 | 179,697,949 |
E0094845590ゼリア新薬工業株式会社Zeria Pharmaceutical Co., Ltd.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2025-04-012026-03-31FY2026-03-312024-04-012025-03-312025-03-311falsefalsefalse455902026-03-31jppfs_cor:CapitalStockMember455902025-04-012026-03-31jppfs_cor:ShareholdersEquityMember455902026-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455902026-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455902026-03-31jppfs_cor:NonControllingInterestsMember455902025-04-012026-03-31jppfs_cor:CapitalStockMember455902025-04-012026-03-31jppfs_cor:CapitalSurplusMember455902025-04-012026-03-31jppfs_cor:RetainedEarningsMember455902025-04-012026-03-31jppfs_cor:TreasuryStockMember455902024-03-31455902026-05-08455902026-03-31455902025-04-012026-03-31455902025-03-31455902024-04-012025-03-31455902025-03-31jppfs_cor:CapitalStockMember455902025-03-31jppfs_cor:CapitalSurplusMember455902025-03-31jppfs_cor:RetainedEarningsMember455902025-03-31jppfs_cor:TreasuryStockMember455902025-03-31jppfs_cor:ShareholdersEquityMember455902025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455902025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455902025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455902025-03-31jppfs_cor:NonControllingInterestsMember455902026-03-31jppfs_cor:CapitalSurplusMember455902026-03-31jppfs_cor:RetainedEarningsMember455902026-03-31jppfs_cor:TreasuryStockMember455902026-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455902026-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455902025-04-012026-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455902025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455902024-04-012025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455902024-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455902025-04-012026-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455902025-04-012026-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455902025-04-012026-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455902025-04-012026-03-31jppfs_cor:NonControllingInterestsMember455902026-03-31jppfs_cor:ShareholdersEquityMember455902024-04-012025-03-31tse-acedjpfr-45590:ConsumerHealthCareBusinessReportableSegmentsMember455902026-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember455902026-03-31jpcrp_cor:ReconcilingItemsMember455902025-04-012026-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember455902025-04-012026-03-31jpcrp_cor:ReconcilingItemsMember455902025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember455902025-03-31jpcrp_cor:ReconcilingItemsMember455902024-04-012025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember455902024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember455902024-03-31jppfs_cor:CapitalStockMember455902024-03-31jppfs_cor:CapitalSurplusMember455902024-03-31jppfs_cor:RetainedEarningsMember455902026-03-31jpcrp_cor:ReportableSegmentsMember455902026-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember455902025-04-012026-03-31jpcrp_cor:ReportableSegmentsMember455902025-04-012026-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember455902025-03-31jpcrp_cor:ReportableSegmentsMember455902025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember455902024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember455902024-04-012025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember455902026-03-31tse-acedjpfr-45590:EthicalDrugBusinessReportableSegmentsMember455902026-03-31tse-acedjpfr-45590:ConsumerHealthCareBusinessReportableSegmentsMember455902025-04-012026-03-31tse-acedjpfr-45590:EthicalDrugBusinessReportableSegmentsMember455902025-04-012026-03-31tse-acedjpfr-45590:ConsumerHealthCareBusinessReportableSegmentsMember455902025-03-31tse-acedjpfr-45590:EthicalDrugBusinessReportableSegmentsMember455902025-03-31tse-acedjpfr-45590:ConsumerHealthCareBusinessReportableSegmentsMember455902024-04-012025-03-31tse-acedjpfr-45590:EthicalDrugBusinessReportableSegmentsMember455902024-03-31jppfs_cor:TreasuryStockMember455902024-03-31jppfs_cor:ShareholdersEquityMember455902024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455902024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455902024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455902024-03-31jppfs_cor:NonControllingInterestsMember455902024-04-012025-03-31jppfs_cor:RetainedEarningsMember455902024-04-012025-03-31jppfs_cor:CapitalStockMember455902024-04-012025-03-31jppfs_cor:CapitalSurplusMember455902024-04-012025-03-31jppfs_cor:TreasuryStockMember455902024-04-012025-03-31jppfs_cor:ShareholdersEquityMember455902024-04-012025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455902024-04-012025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455902024-04-012025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455902024-04-012025-03-31jppfs_cor:NonControllingInterestsMemberxbrli:pureiso4217:JPY